Chime Biologics, a leading global CDMO that enables its partners' success in biologics, and Waterstone, a reliable partner ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

Entero has signed a binding term sheet in which private biotech Journey is slated to acquire 99% of Entero’s equity, ...

Swiss CDMO Lonza is bulking up its bioconjugation manufacturing digs with two new multicustomer suites and 200 new jobs at ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

Araris Biotech is a pioneering leader in the development of antibody-drug conjugates (ADCs) with the potential for unparalleled efficacy and tolerability. The Araris ADC technology AraLinQ™ enables ...

Press Release: Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem First characterization of its novel conjugation technology for creating ...

Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit -BOSTON and LONDON, Nov. 14, ...

Following the clearance of an investigational new drug application from the FDA, a phase 1 trial will examine the novel ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

NextCure is going all in on its preclinical B7-H4-directed antibody-drug conjugate (ADC). | NextCure is going all in on its ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting ...